EWEmma Wischlen

Emma Wischlen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emma Wischlen has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Jérôme Dumortier

    Hospices civils de Lyon, Edouard Herriot hospital, Department of Digestive Diseases, Lyon, France; Claude Bernard Lyon 1 University, Lyon, France

    5 shared publications
  • Valérie Hervieu

    Department of Pathology, Groupe Hospitalier Est, Hospices Civils de Lyon, Bron, France

    5 shared publications
  • Olivier Boillot

    Department of Digestive Diseases, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France

    4 shared publications
  • Alain Lachaux

    Department of Pediatric Hepato-Gastroenterology and Nutrition, Femme-Mère-Enfants University Hospital, Hospices Civils de Lyon, Bron, France

    3 shared publications
  • Christine Rivet

    Department of Pediatric Hepato-Gastroenterology and Nutrition, Femme-Mère-Enfants University Hospital, Hospices Civils de Lyon, Bron, France

    3 shared publications
  • Noémie Laverdure

    Department of Pediatric Hepato-Gastroenterology and Nutrition, Femme-Mère-Enfants University Hospital, Hospices Civils de Lyon, Bron, France

    3 shared publications

Latest Publications

  • Dynamics and risk factors for long term pediatric liver graft fibrosis progression according to protocol liver biopsies over a 30-years follow-up

    by Olivier Boillot, Emma Wischlen, Valérie Dubois, Sophie Chopinet, Noémie Laverdure, Valérie Hervieu, Sophie Collardeau-Frachon, Christine Rivet, Alain Lachaux, Jérôme Dumortier


  • Donor HLA Class I Evolutionary Divergence and Late Allograft Rejection After Liver Transplantation in Children: An Emulated Target Trial

    by Jérôme Dumortier, Sarah Hamada, Emma Wischlen, Céline Mandier, Noémie Laverdure, Olivier Boillot, Ilias Kounis, Vincent Allain, Valérie Hervieu, Sophie Collardeau‐Frachon, et al.

    HLA evolutionary divergence (HED), a continuous metric quantifying the differences between each amino acid of two homologous HLA alleles, reflects the importance of the immunopeptidome presented to T lymphocytes. It has been associated with rejection after liver transplantation. This retrospective cohort study aimed to analyse the potential effect of donor or recipient HED on liver transplant rejection in a new series of patients transplanted during childhood and followed in adulthood. The study included 120 children who had been transplanted between 1991 and 2010 and were followed by routine biopsies and histological evaluations with a median of 14.1 years post‐LT. Liver biopsies were performed routinely 1, 5, 10 and 20 years after transplantation and in the event of liver dysfunction. HED was calculated using the physicochemical Grantham distance for donor and recipient Class I (HLA‐A, ‐B, ‐C) and Class II (HLA‐DRB1, ‐DQB1) alleles. The influence of HED on rejection was analysed using inverse probability weighting (IPW) and target trial emulation using the g method. Based on the IPW score, donor HED class I was correlated with the occurrence of late (> 90 days) rejection (HR, 1.19, 95% CI: 1.01–1.40) independently of HLA mismatches, donor age and initial induction. The emulated target trial confirmed that donor HED Class I has a causal effect on liver graft rejection and this relationship was observed long‐term.


  • Steatotic liver disease after pediatric liver transplantation

    by Emma Wischlen, Olivier Boillot, Christine Rivet, Alain Lachaux, Raymonde Bouvier, Valérie Hervieu, Jean-Yves Scoazec, Sophie Collardeau-Frachon, Jérôme Dumortier, Noémie Laverdure

    Metabolic dysfunction–associated steatotic liver disease is becoming an increasingly frequent cause of chronic liver disease in children. It has been reported as a complication of liver transplantation in adults but remains poorly evaluated in liver-transplanted children. The aim of this study was to assess the prevalence and characteristics of steatotic liver disease in a large cohort of liver-transplanted children and to identify factors associated with it. In this single-center study of patients with pediatric liver transplants (n=122) with a median follow-up time of 14.0 years, steatosis was found in 41 protocol biopsies (33.6%). The median time to the discovery of steatosis was 5.0 years posttransplantation, with a median age of 9.0 years at the time of diagnosis. Steatosis was predominantly mild to moderate and tended to resolve spontaneously on subsequent biopsies (48.8% of cases showed resolution). Steatosis mostly corresponded to metabolic dysfunction–associated steatotic liver disease (56.1%), but other patients had cryptogenic steatosis. The study found no association between the presence of steatosis and the immunosuppressive regimen, but a significant association between the onset of steatosis and an older donor age ( p <0.001). Therefore, steatotic liver disease is a noteworthy histological feature during the follow-up of pediatric liver transplant recipients, yet it had a low burden on the health of the patients in this cohort. However, it needs to be monitored in the context of the increasing prevalence of metabolic syndrome.

  • Iterative antibody-induced bile salt export pump deficiency after successive liver transplantations successfully treated with plasmapheresis and rituximab

    by Emma Wischlen, Noémie Laverdure, Domitille Erard, Barbara Rohmer, Olivier Boillot, Rémi Dubois, Alain Lachaux, Sophie Collardeau-Frachon, Valérie Hervieu, Jérôme Dumortier


  • Are protocol graft biopsies after pediatric liver transplantation useful? Experience in a single center over 20 years

    by Emma Wischlen, Olivier Boillot, Christine Rivet, Alain Lachaux, Raymonde Bouvier, Valérie Hervieu, Jean‐Yves Scoazec, Sophie Collardeau‐Frachon, Jérôme Dumortier, Noémie Laverdure

    Background: The role of protocol liver biopsies (PLB) in the follow‐up of pediatric liver transplant recipients remains questionable. This single‐center retrospective study aimed to evaluate their clinical impact on the long‐term management of pediatric liver transplant recipients.Methods: We described histopathological lesions and clinical consequences for patient management of PLB performed 1, 5, 10, 15, 20, and 25 years after pediatric liver transplantation (LT).Results: A total of 351 PLB performed on 133 patients between 1992 and 2021 were reviewed. PLB found signs of rejection in 21.7% of cases (76/351), and moderate to severe fibrosis in 26.5% of cases (93/351). Overall, 264 PLB (75.2%) did not cause any changes to patient care. Immunosuppression was enhanced after 63 PLB, including 23 cases of occult rejection. The 1‐year PLB triggered significantly more changes, while biopsies at 15, 20, and 25 years produced the lowest rates of subsequent modifications. PLB had a significantly higher probability of inducing therapeutic changes if the patient had abnormal biological or imaging results (odds ratio [OR] 2.82 and 2.06), or a recent history of rejection or bacterial infection (OR 2.22 and 2.03).Conclusion: Our results suggest that, although it often does not prompt any treatment changes, PLB could be performed because of its ability to detect silent rejection requiring an increase in immunosuppression. PLB could be carried out 1, 5, and 10 years after LT and then every 10 years in patients with normal biological and imaging results and no recent complications, while other patients could be kept on a 5‐year protocol.